Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Meeting Abstract

    Porta, C. G.; Eto, M.; Motzer, R. J.; De Giorgi, U. F. F.; Buchler, T.; Basappa, N. S.; Vidal, M. J. M.; Tjulandin, S.; Park, S. H.; Melichar, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Association between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced first-line (1L) renal cell carcinoma (aRCC): Exploratory analyses from CheckMate 9ER (CM 9ER)
    Meeting Abstract

    Cella, D.; Porta, C. G.; Hamilton, M.; Ejzykowicz, F.; Blum, S. I.; Ivanescu, C.; Rodriguez, C. S.; Choueiri, T. K.; Motzer, R. J.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Escudier, B.; Motzer, R. J.; Dyer, M.; May, J. R.; Ejzykowicz, F.; Kurt, M.; Lee, C. W.; Wang, P.; Testa, E.; Sharpe, D. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era
    Meeting Abstract

    Thouvenin, J.; Alhalabi, O.; Carlo, M.; Ajuria, L. C.; Bakouny, Z.; Chanza, N. M.; Negrier, S.; Campedel, L.; Bilen, M. A.; Borchiellini, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer
    Meeting Abstract

    Linch, M.; Liu, G.; Crabb, S. J.; Beer, T. M.; Heath, E.; Gordon, M.; de Bono, J. S.; Pashova, H. I.; Tudor, I. C.; Custodio, J. M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J.; Tagawa, S. T.; Slovin, S.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; Autio, K.; Xiao, H.; Molina, A. M.; Eickhoff, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Associations between metformin and mortality risks in Asian diabetic patients with prostate cancer undergoing androgen deprivation therapy: A retrospective cohort study
    Meeting Abstract

    Lee, Y. H. A.; Hui, J. M. H.; Chan, J. S. K.; Liu, K.; Dee, E. C.; Ng, K.; Tang, P.; Tse, G.; Ng, A. C. F.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
    Meeting Abstract

    Albiges, L.; Gurney, H. P.; Atduev, V.; Suarez, C.; Duran, M. A. C.; Pook, D.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Gupta, S.; Yang, Q.; Halabi, S.; Tubbs, A.; Gore, Y.; George, D. J.; Nanus, D. M.; Antonarakis, E. S.; Danila, D.; Szmulewitz, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castrationresistant prostate cancer in the VISION trial
    Meeting Abstract

    Armstrong, A. J.; Sartor, O.; Saad, F.; Czernin, J.; Shore, N. D.; Kendi, A. T.; Beer, T. M.; Vaishampayan, N.; El-Haddad, G.; Wu, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save